All News
Taking a closer look: B-Cell depletion beyond the blood
Following the landmark case series by the Erlangen group, multiple cellular therapies have entered the race—each with unique targets, constructs, and mechanisms. Yet, a fundamental question remains: How deep is the B-cell depletion? In clinical practice, peripheral blood counts often serve as our surrogate for depletion. But these may only tell part of the story.
Read Article
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI
AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. Ankylosing spondylitis, in particular, poses a diagnostic challenge—its early imaging findings are subtle, and radiographic changes may take years to appear and require specific musculoskeletal radiology expertise. A new deep learning model offers a glimpse into how AI could bridge this diagnostic gap.
Read Article
GLP-1 and SGLT-2: Treatments Too Good to Ignore?
Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658.
https://t.co/OclO05bpku https://t.co/kASID9jnAP
Dr. John Cush RheumNow ( View Tweet)
B Cell Depletion: Check the Lymph Node
Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25.
https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q
Dr. John Cush RheumNow ( View Tweet)
🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology!
🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement!
👉You can read the manuscript in this link: https://t.co/teEscaBVG3
#EMEUNET https://t.co/BKRXTXiQ8U
Links:
EMEUNET EMEUNET ( View Tweet)
Join us as we celebrate & congratulate, Eric L. Matteson, MD, MPH, recipient of the 2025 ACR Presidential Gold Medal Award! 🌟 VIEW → https://t.co/ZcIXeZbAKr @MayoClinic #ACR25 https://t.co/7G07K7ZkjS
Links:
American College of Rheumatology ACRheum ( View Tweet)
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @UNMC_Rheum
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumX #RheumTwitter #ACR2025 https://t.co/rgOb4ZV4r8
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
This and other reports on palindromic rheumatism show that PR is a pre-clinical RA state, both having same predictive factors for progression to RA! https://t.co/jfpraGfe72
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: Which biologic agent is the best first choice?
A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
https://t.co/pRMyPCvMrN https://t.co/nOgnf5F3Pw
Dr. John Cush RheumNow ( View Tweet)
Should we be using JAKi more in female SpA patients?
In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR25 Topic Panels — LIVE!
Nov. 4 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: CAR-T
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/zedho2RI6T
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults
In RA alone, nearly 40% of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental https://t.co/2pqXGURQtL
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in AxSpA in Developing Countries
Dr. Antoni Chan reports on abstracts 0582 and abstract 0554 presented at #ACR25
https://t.co/4kTv90PhIC https://t.co/WRUBP0O21b
Links:
Dr. John Cush RheumNow ( View Tweet)
900,000 vs 9
It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed.
It takes less than nine minutes to make your patient feel seen, understood and reassured.
If you skip the 9 minutes, you wasted the https://t.co/DBoteUTavZ
Dr. John Cush RheumNow ( View Tweet)
Topline results of ALLEGORY study (Genentech) - 300 pt. phase 3 DBRPCT obinuntuzumab vs PBO in active SLE w/ SRI-4 primary outcome at wk 52. The anti-CD20, B-cell depleter, Rx met all efficacy endpoints primary and all key secondary endpoints. Gazyva was FDA approved last wk https://t.co/Wd6EFEjvGP
Dr. John Cush RheumNow ( View Tweet)
Difficult to Manage axSpA
Drs. Antoni Chan and Rodrigo Garcia Salinas discuss abstract 0584, "Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns", presented at #ACR25 https://t.co/84HZojI3FJ
Dr. John Cush RheumNow ( View Tweet)
FDA is going to "fast-track" biosimilars to curtail the costs of expensive biologics https://t.co/h5NBsUaM97
Dr. John Cush RheumNow ( View Tweet)
Not only lovely work @TheLancetRheum from @jeffsparks and friends, but they have some AI imaging work up tomorrow from the same SAIL-RA cohort, showing the spectrum of impact in all RA patients, using radiomics.
Check it out #ACR25 ABST1751 @RheumNow
https://t.co/TlmHOOpNNp https://t.co/P62RXI8ePQ
Links:
David Liew drdavidliew ( View Tweet)
A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH.
What is the most likely diagnosis? https://t.co/afPUeaqfZT
Dr. Nikhil Agrawal DrNikhilMD ( View Tweet)
